Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma

References

• Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044–9
   PubMed Web of Science ®Google Scholar
• Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J 2000; 6: 179–87
   Google Scholar
• Bay JO, Choufi B, Pomel C, et al. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 2000; 25: 681–2
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409–15
   PubMed Web of Science ®Google Scholar
• Bay JO, Fleury J, Choufi B, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002; 30: 95–102
   PubMed Web of Science ®Google Scholar
• Hanel M, Bornhauser M, Muller J, et al. Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol 2003; 129: 12–16
   PubMed Web of Science ®Google Scholar
• Donato ML, Levenback C, Gershenson DM, et al. Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol 2004; 92: 365–7
   Google Scholar
• Kasow KA, Handgretinger R, Krasin MJ, et al. Possible allogeneic graft-versus-tumor effect in childhood melanoma. J Pediatr Hematol Oncol 2003; 25: 982–6
   Google Scholar
• Kurokawa T, Fischer K, Bertz H, et al. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer 2002; 101: 52–60
   Google Scholar
• Childs R, Bradstock K, Gottlieb D , et al. Non-myeloablative allogeneic stem cell transplantation for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-versus-tumor effects. Blood 2002;100: 429a abstract 1661.
   Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–57
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332–42
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Li YC, Lionello I, et al. Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. Br J Cancer 2006; 95: 181–8
   PubMed Web of Science ®Google Scholar
• Meisenberg B. High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma. Bone Marrow Transplant 1996; 17: 903–6
   PubMed Web of Science ®Google Scholar
• Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996; 156: 1126–31
   PubMed Web of Science ®Google Scholar
• Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996; 156: 465–72
   PubMed Web of Science ®Google Scholar
• Rudy W, Guckel B, Siebels M, et al. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. Int Immunol 1997; 9: 853–60
   PubMed Web of Science ®Google Scholar
• Dummer R, Yue FY, Pavlovic J, et al. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br J Cancer 1998; 77: 1413–19
   Google Scholar
• McCarthy DO, Glowacki N, Schell K, et al. Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunol Immunother 2000; 49: 85–93
   Google Scholar
• Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791–6
   PubMed Web of Science ®Google Scholar
• Dohring C, Angman L, Spagnoli G, et al. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994; 57: 754–9
   PubMed Web of Science ®Google Scholar
• Guerder S, Carding SR, Flavell RA. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol 1995; 155: 5167–74
   Google Scholar
• Plumas J, Chaperot L, Jacob MC, et al. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells. Eur J Immunol 1995; 25: 3332–41
   PubMed Web of Science ®Google Scholar
• Yang S, Darrow TL, Seigler HF. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Cancer Res 1997; 57: 1561–8
   PubMed Web of Science ®Google Scholar
• Kahn M, Sugawara H, McGowan P, et al. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991; 146: 3235–41
   Google Scholar
• Shinomiya Y, Harada M, Kurosawa S, et al. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells. Immunobiology 1995; 193: 439–55
   Google Scholar
• Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major ‘post-licensing’ role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047–55
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101: 2686–92
   PubMed Web of Science ®Google Scholar
• Beatty PA, Greenberg PD, Cheever MA. Adoptive immunotherapy of metastatic B16 melanoma with allogeneic immune cells sensitized to minor histocompatibility antigens. Transplantation 1985; 39: 182–6
   Google Scholar